NCT04583800 Prediction of Heart Failure and Cognitive Decline in Type 2 Diabetes
| NCT ID | NCT04583800 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2021-06-22 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2021-06-22 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Type 2 diabetes is a risk factor of heart failure and cognitive decline. Heart failure at its early stage is often silent. At present, primary prevention for heart failure is not available. Our aim is to identify diabetic patients at risk of heart failure in order to develop personalized preventive strategies. Type 2 diabetes is vascular and metabolic risk factor for cognitive decline though a direct lesional effect but also through an interaction with underlying neurodegenerative lesions. Our aim is to identify diabetic patients at risk of cognitive decline in order to develop personalized preventive strategies
Eligibility Criteria
Inclusion Criteria: * Adults * Persons able to understand and object to the information provided. * Type 2 diabetic patient free of heart failure ≥stade B * Patient affiliated with a social security scheme. * Patient agreeing to sign the informed consent form Exclusion Criteria: * Patient with dementia * Patient with at least one of the criteria for heart failure ≥stade B
Contact & Investigator
Charlotte Cordonnier, MD,PhD
PRINCIPAL INVESTIGATOR
University Hospital, Lille
Frequently Asked Questions
Who can join the NCT04583800 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04583800 currently recruiting?
Yes, NCT04583800 is actively recruiting participants. Contact the research team at precidiab_heart_brain@chru-lille.fr for enrollment information.
Where is the NCT04583800 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT04583800 clinical trial?
NCT04583800 is sponsored by University Hospital, Lille. The principal investigator is Charlotte Cordonnier, MD,PhD at University Hospital, Lille. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.